Johnson & Johnson, the American health company, continues to supply Acuvue contact lenses to Russian consumers, according to the company’s press office as reported by DEA News. The message is clear: access to health products matters, even in challenging markets, and the company asserts its willingness to serve customers across borders with its eyewear lines.
Officials stressed that patient access to essential health products remains a fundamental priority. The company indicated that its overarching aim is to provide products to customers in multiple countries, underscoring a commitment to global availability while navigating a complex regulatory landscape.
Market participants, cited by Kommersant FM, note that Johnson & Johnson, which sells Acuvue Oasys and Acuvue True Eye lenses among others, has begun notifying market players about suspending imports of its products into Russia. This development follows schedules of regulatory checks and market conditions that affect the flow of branded contact lenses into the country.
Concerns raised by the Consumers Union suggest there is friction involving the Federal Antimonopoly Service (FAS) and its role in the distribution of contact lenses. The union argues that regulatory actions have a direct impact on how brands reach consumers, particularly in fast-moving sectors like vision care.
Concurrently, Russia’s Ministry of Industry and Trade has stated that contact lenses may be included in a list for parallel imports, a move that could alter how foreign brands enter the market and how consumers access replacement lenses. This development signals ongoing government consideration of supply channels and consumer choice in the optical sector.
Across North America, observers note that the balance between regulatory oversight, cross-border commerce, and patient access continues to shape the availability of popular lens brands. Stakeholders in Canada and the United States watch closely as manufacturers weigh regional distribution strategies, support for eye health, and compliance with local regulatory standards while maintaining the integrity of their product lines. The evolving situation highlights how global health brands adapt to sanctions, import controls, and market-specific policies while aiming to keep patients well supplied with reliable, prescription-grade lenses [DEA News; Kommersant FM; Consumers Union].